Gene · 51135
Papers3,419
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 3,419
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Histone H4 lysine 20 tri-methylation safeguards breast cancer lineage fidelity and unfolded protein response. | Nat Commun | 2026 | 42802180 | PubTator, text mining | PubMed |
| Machine Learning-Driven Drug Repositioning Identifies Putative IRAK4 Inhibitors Through Structure-Based Computational Evaluation. | Curr Issues Mol Biol | 2026 | 42793211 | PubTator, text mining | PubMed |
| Non-canonical signaling hubs upon inhibition of MyD88-ERK interaction in cancer. | Cell Death Dis | 2026 | 42791244 | PubTator, text mining | PubMed |
| The E3 ubiquitin ligase HECTD3 controls immune colonic inflammation by restricting MyD88 activation and signaling. | JCI Insight | 2026 | 42784256 | PubTator, text mining | PubMed |
| Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials. | Commun Med (Lond) | 2026 | 42749863 | PubTator, text mining | PubMed |
| Local ancestry inference identifies robust evidence of selection in Neolithic Europe. | Mol Biol Evol | 2026 | 42749287 | PubTator, text mining | PubMed |
| A possible founder IRAK4 variant in Okinawa, Japan. | J Hum Immun | 2026 | 42742462 | PubTator, text mining | PubMed |
| Discovery of JH-XIII-05-01, a First-in-Class Dual IRAK1/IRAK4 Degrader for MYD88 Mutant Lymphomas. | ACS Med Chem Lett | 2026 | 42741641 | PubTator, text mining | PubMed |
| Structural optimization of 2-(2-aminopyridin-4-yl)-N-(3-carbamoyl-1H-pyrazol-4-yl)-1,3-oxazole-4-carboxamide derivatives as potent interleukin-1 receptor-associated kinase 4 inhibitors. | Bioorg Med Chem | 2026 | 42735465 | PubTator, text mining | PubMed |
| CFTR regulates lipid metabolism by relieving adipose inflammation in obesity. | Int J Obes (Lond) | 2026 | 42668310 | PubTator, text mining | PubMed |
| Clinical pearls and pitfalls in inborn errors of immunity: An expert-derived framework for diagnostic pattern recognition. | Pediatr Allergy Immunol | 2026 | 42634355 | PubTator, text mining | PubMed |
| IRAK4 compound heterozygous variants: careful evaluation between NASA syndrome and classical IRAK4 deficiency. | Gene | 2026 | 42607850 | PubTator, text mining | PubMed |
| Gut microbiota-derived TMA/TMAO and IRAK4 signaling in type 2 diabetes: Current evidence, knowledge gaps and future therapeutic opportunities. | Int Immunopharmacol | 2026 | 42594838 | PubTator, text mining | PubMed |
| Structure-Based Drug Design of Novel Indazole/Indolinone-Based Biaryl Derivatives as Oral IRAK4 Inhibitors for the Treatment of Inflammatory Diseases. | J Med Chem | 2026 | 42593912 | PubTator, text mining | PubMed |
| XunZi, an AI biologist, reveals disease-modifying targets. | Nat Biomed Eng | 2026 | 42552442 | PubTator, text mining | PubMed |
| PROTAC-mediated regulation of programmed cell death: From molecular mechanisms to therapeutic breakthroughs. | Innovation (Camb) | 2026 | 42422020 | PubTator, text mining | PubMed |
| Emerging synthetic drugs for the management of hidradenitis suppurativa: a comprehensive update. | Expert Opin Pharmacother | 2026 | 42342652 | PubTator, text mining | PubMed |
| Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib. | Mol Cancer Ther | 2026 | 42338303 | PubTator, text mining | PubMed |
| Structural basis for selective and potent degradation of IRAK4 by KT-474. | Nat Commun | 2026 | 42336816 | PubTator, text mining | PubMed |
| Small molecules and their importance as therapeutic options in daily practice. | Ann Allergy Asthma Immunol | 2026 | 42320562 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51135/papers